Fidson Healthcare
On this page
Company details
- Legal name
- Fidson Healthcare Plc
- Listing
- FIDSON on the Nigerian Exchange, active · ISIN NGFIDSON0006 (observed 2026-10-08)
- Sector
- Not classified (our classification from the stated principal activity)
- Financial year ends
- 31 December
Overview
Year ended 31 December 2025 · annual report, signed / final · source
-
Revenue
NGN 119 billion
119,061,254 NGN thousands · p27
+41.4% vs 2024
-
Operating profit / (loss)
NGN 21.9 billion
21,948,612 NGN thousands · p27
+67.1% vs 2024
-
Profit / (loss) for the year
NGN 9.88 billion
9,883,576 NGN thousands · p27
+124.7% vs 2024
-
Total assets
NGN 80.3 billion
80,286,939 NGN thousands · p28
+9.2% vs 2024
-
Total equity
NGN 30.2 billion
30,196,827 NGN thousands · p28
+35.1% vs 2024
-
Cash from operations
NGN 16.8 billion
16,821,008 NGN thousands · p30
Change not shown.
Large amounts are rounded for reading (NGN million / billion / trillion); exact figures as printed are under each amount and in the tables. No currency conversion.
Not shown: the prior-year figure is zero or negative.
Business overview
Fidson Healthcare manufactures and distributes pharmaceutical products; the notes describe its operations as based in Nigeria and other West African countries. It reports a single segment but classifies revenue into four product categories: ethical (prescription-only drugs, injectables and infusions), over-the-counter products, toll manufacturing for other companies, and exports. Ethical products made up 65.4% of FY2025 revenue and over-the-counter products 30.5%. Its largest customer accounted for about NGN 4.98 billion of FY2025 revenue.
Source: Annual report 2025, p31, p77
Financial trends
FY2024 (restated) and FY2025, company statements, in Nigerian naira (nominal).
- Comparing FY2024 with FY2025, revenue rose 41.4% in nominal naira terms, from NGN 84.2 billion to NGN 119 billion, and operating profit rose from NGN 13.1 billion to NGN 21.9 billion, taking operating profit as a share of revenue from 15.6% to 18.4%. Operating profit is stated after net exchange losses of NGN 5.45 billion in FY2024 and NGN 6.01 billion in FY2025.
- Net cash flows from operating activities moved from an outflow of NGN 649 million in FY2024 to an inflow of NGN 16.8 billion in FY2025, which covered purchases of property, plant and equipment of NGN 8.02 billion and dividends paid of NGN 2.29 billion that year. Prepayments fell from NGN 12.5 billion at the end of FY2024 to NGN 6.54 billion at the end of FY2025.
- Interest-bearing loans and borrowings (current plus non-current) fell from NGN 16.0 billion at the end of FY2024 to NGN 14.0 billion at the end of FY2025, while commercial paper, shown as other financial liabilities, rose from NGN 15.6 billion to NGN 19.6 billion over the same dates. (Annual report 2025, p73)
The filings collected for this profile cover two annual periods, FY2024 and FY2025.
Growth is in nominal naira; no adjustment is made for inflation or exchange-rate movements.
How the calculated figures are worked out
- Ethical share of FY2025 revenue: Ethical, revenue 31-Dec-25, FY2025 (annual report 2025, p77) ÷ Revenue FY2025 (annual report 2025, p27) × 100 = 65.4%
- OTC share of FY2025 revenue: Over-The-Counter, revenue 31-Dec-25, FY2025 (annual report 2025, p77) ÷ Revenue FY2025 (annual report 2025, p27) × 100 = 30.5%
- Revenue change FY2024 to FY2025: (Revenue FY2025 (annual report 2025, p27) − Revenue FY2024 (annual report 2025, p27)) ÷ Revenue FY2024 (annual report 2025, p27) × 100 = 41.4%
- Operating profit / revenue FY2024: Operating profit FY2024 (annual report 2025, p27) ÷ Revenue FY2024 (annual report 2025, p27) × 100 = 15.6%
- Operating profit / revenue FY2025: Operating profit FY2025 (annual report 2025, p27) ÷ Revenue FY2025 (annual report 2025, p27) × 100 = 18.4%
- Interest-bearing loans and borrowings FY2024: Interest bearing loans and borrowings FY2024 (annual report 2025, p28) + Interest bearing loans and borrowings FY2024 (annual report 2025, p28) = NGN 16.0 billion
- Interest-bearing loans and borrowings FY2025: Interest bearing loans and borrowings FY2025 (annual report 2025, p28) + Interest bearing loans and borrowings FY2025 (annual report 2025, p28) = NGN 14.0 billion
Calculated by us from the figures in the tables below; rounded once, at the end, to the places shown. Not part of the published statements or the CSV.
Business overview and trends written from the company's filings cited above and checked with AI assistance on 18 October 2026; not independently reviewed. Historical figures only: not investment advice, a valuation or a forecast.
Financial statements
Exact figures as printed. Each column comes from one filing; labels are as printed in the newest filing. Amounts in NGN thousands unless the row says otherwise; brackets are negative.
† from a supplementary filing for the same year · ‡ signed audited statements preferred over a disputed figure · “–” is a printed dash, explained below the table
Column sources
- FY2025 — annual report, signed / final; reported for the year · source
- FY2024 — annual report, signed / final; comparative in the FY2025 filing · source
Income statement
| Line (as printed) | FY2025Annual reportreported for the year | FY2024Annual reportcomparative in FY2025 filing |
|---|---|---|
| Revenue | 119,061,254 | 84,189,000 |
| Cost of Sales | (69,835,197) | (49,084,616) |
| Gross profit | 49,226,057 | 35,104,384 |
| Other gains and losses | 887,547 | 611,871 |
| Administrative expenses | (12,396,055) | (8,712,125) |
| Impairment of receivables | (133,069) | (301,440) |
| Net exchange loss | (6,012,067) | (5,448,891) |
| Selling and distribution expenses | (9,623,801) | (8,119,539) |
| Operating profit | 21,948,612 | 13,134,260 |
| Finance costs | (7,130,319) | (5,493,822) |
| Finance income | 144,315 | 60,022 |
| Profit before tax | 14,962,608 | 7,700,460 |
| Income tax * | (5,079,032) | (3,301,497) |
| Profit for the year * | 9,883,576 | 4,398,964 |
| Other comprehensive income, net of tax; | 30,242 | 30,198 |
| Total comprehensive income, net of tax * | 9,913,818 | 4,429,162 |
Balance sheet
| Line (as printed) | FY2025Annual reportreported for the year | FY2024Annual reportcomparative in FY2025 filing |
|---|---|---|
| Property, plant and equipment | 30,937,846 | 25,125,748 |
| Right of use of assets | –1 | –1 |
| Intangible assets | 238,235 | 65,471 |
| Financial assets at FVTOCI | 12,360 | 9,100 |
| Financial assets at amortised cost | 20,498 | 17,915 |
| Other non-current financial asset2 | 215,936 | 198,106 |
| Non-current assets (unlabelled subtotal) | 31,424,875 | 25,416,340 |
| Inventories | 26,547,162 | 24,182,294 |
| Financial assets at amortised cost | –3 | 242,230 |
| Trade and other receivables | 11,068,227 | 6,208,214 |
| Prepayments4 | 6,535,857 | 12,513,033 |
| Cash and cash equivalents | 4,710,818 | 4,931,368 |
| Total current assets | 48,862,064 | 48,077,140 |
| Total assets | 80,286,939 | 73,493,480 |
| Share capital | 1,200,000 | 1,147,498 |
| Share premium | 5,009,225 | 4,829,614 |
| Retained earnings * | 23,979,687 | 16,364,125 |
| Financial asset reserve | 7,915 | 4,655 |
| Total equity | 30,196,827 | 22,345,892 |
| Interest bearing loans and borrowings | 3,596,236 | 7,018,279 |
| Retirement benefit obligation | 160,139 | 251,090 |
| Government grant5 | 207,267 | 590,618 |
| Deferred tax liability * | 4,676,505 | 3,836,609 |
| Non-current liabilities (unlabelled subtotal) | 8,640,147 | 11,696,596 |
| Trade and other payables | 6,630,781 | 10,370,733 |
| Interest bearing loans and borrowings | 10,407,067 | 8,979,029 |
| Bank Overdraft | 9,528 | 1,283,797 |
| Other financial liabilities6 | 19,645,345 | 15,646,950 |
| Government grant5 | 427,488 | 687,468 |
| Income tax payable | 4,250,709 | 2,349,129 |
| Unclaimed dividend7 | 79,048 | 133,887 |
| Current liabilities (unlabelled subtotal) | 41,449,966 | 39,450,993 |
| Total liabilities | 50,090,112 | 51,147,589 |
| Total equity and liabilities | 80,286,939 | 73,493,480 |
- Printed “-”, read as nil: subtotal_arithmetic: bs.non_current_assets.
- Printed “-”, read as nil: subtotal_arithmetic: bs.current_assets.
Notes and alternative reported figures (5)
- “Other non-current financial asset” is an issuer-specific line, not mapped to a shared definition: Note 19.
- “Prepayments” is an issuer-specific line, not mapped to a shared definition: Note 22: current; printed apart from trade and other receivables.
- “Government grant” is an issuer-specific line, not mapped to a shared definition: Note 26: deferred government grant.
- “Other financial liabilities” is an issuer-specific line, not mapped to a shared definition: Current (note 28).
- “Unclaimed dividend” is an issuer-specific line, not mapped to a shared definition: Current (note 29(b)).
Cash flow
| Line (as printed) | FY2025Annual reportreported for the year | FY2024Annual reportcomparative in FY2025 filing |
|---|---|---|
| Cash generated from operations (unlabelled subtotal) | 19,170,128 | 189,984 |
| Income tax paid | (2,349,120) | (839,094) |
| Net cash flows generated / (used in) from operating activities | 16,821,008 | (649,110) |
| Purchase of property, plant & equipment | (8,016,748) | (3,693,094) |
| Additions to intangible assets | (463,131) | (175,489) |
| Interest received | 119,028 | 44,617 |
| Proceeds from sale of property, plant and equipment | 96,155 | 2,970 |
| Proceeds from sale of right of use asset1 | –2 | 336 |
| Net cash flows utilized by investing activities | (8,264,696) | (3,820,660) |
| Interest paid on borrowings | (3,941,758) | (1,796,209) |
| Interest paid on financial liabilities3 | (2,464,168) | (3,152,716) |
| Dividend paid | (2,294,996) | (1,376,998) |
| Received/(Refund) of unclaimed dividend4 | (54,839) | 33,142 |
| Proceed from loans & borrowings | 6,000,000 | 8,300,000 |
| Proceed from other financial liabilities5 | 19,645,345 | 15,646,950 |
| Loan repayment (Principal)- Other financial liabilities6 | (15,646,950) | (10,000,000) |
| Loan repayment (Principal) | (8,709,925) | (9,685,504) |
| Net cash flows used in financing activities | (7,467,291) | (2,031,334) |
| Net increase/ (decrease) in cash and cash equivalents | 1,089,021 | (6,501,104) |
| Effect of foreign exchange difference | (35,302) | 143,816 |
| Cash and cash equivalents at beginning of year | 3,647,571 | 10,004,859 |
| Cash and cash equivalents, at end of the year | 4,701,290 | 3,647,571 |
- Printed “-”, read as nil: subtotal_arithmetic: cf.cash_from_investing.
Notes and alternative reported figures (5)
- “Proceeds from sale of right of use asset” is an issuer-specific line, not mapped to a shared definition: Investing activities.
- “Interest paid on financial liabilities” is an issuer-specific line, not mapped to a shared definition: Financing activities (note 11).
- “Received/(Refund) of unclaimed dividend” is an issuer-specific line, not mapped to a shared definition: Financing activities (note 29(b)).
- “Proceed from other financial liabilities” is an issuer-specific line, not mapped to a shared definition: Financing activities (note 28).
- “Loan repayment (Principal)- Other financial liabilities” is an issuer-specific line, not mapped to a shared definition: Financing activities (note 28).
Segments
Segment data not yet collected for this company in the pilot.
Dividends
Proposed or recommended, declared and paid are different events and are kept apart. A statement that no dividend was proposed does not mean none was paid.
| Year ended | Event | Wording as printed | Amount | Unit | Source |
|---|---|---|---|---|---|
| 31 Dec 2025 | Dividends paid (cash flow statement) | Dividend paid |
(2,294,996) | NGN thousands | Annual report, p30 |
| 31 Dec 2024 | Dividends paid (cash flow statement) | Dividend paid |
(1,376,998) | NGN thousands | Annual report, p30 |
Sources
Each filing used on this page, newest period first. Dates are the document's own; the date we retrieved a file is shown separately and is never a publication date.
-
Fidson Healthcare Plc Annual Report and Financial Statements for the year ended 31 December 2025
Year ended 31 December 2025 · Annual report · signed / final
Audit: Deloitte & Touche (Chartered Accountants), Lagos, unmodified opinion · signed
Auditor's sign-off: Folorunso Hunga, FCA, for Deloitte & Touche
Final status: Independent auditor's report to the shareholders of Fidson Healthcare Plc (scanned, PDF pp22-24; opinion p22) signed by hand for Deloitte & Touche (Folorunso Hunga, FCA, FRC/2013/PRO/ICAN/004/00000001709) with the ICAN seal, 'Lagos, Nigeria, 31 March 2026' (the day handwritten), PDF p24, page image. The statement of financial position was 'Signed on Behalf of the Board of Directors on 26th March 2026' with handwritten signatures of Abiola Adebayo (Managing Director/CEO) and Imokha Ayebae (Finance Director) (PDF p28, also p21, page image).
- Document date
- 31 Mar 2026
- Auditor's report
- 31 Mar 2026
- Board approval
- 26 Mar 2026
- Retrieved by us
- 8 Oct 2026 (not a publication date)
- Used for
- statement columns FY2025, FY2024
- Basis
- company statements · NGN thousands (printed “N '000”)
- Cash and cash equivalents at the end of the year in the cash flow statement (4,701,290; 2024: 3,647,571, p30) are net of the bank overdraft (9,528; 2024: 1,283,797) printed under current liabilities (p28); balance-sheet cash is 4,710,818 (2024: 4,931,368).
- The signed statement of financial position (folio 26) is printed twice: at PDF p21, before the scanned auditor's report, and at p28 in sequence; both pages carry the same text layer and figures. Transcribed from p28.
- Note 44 (PDF p84): the 2024 comparatives are restated for an understatement of deferred tax (wrong calculation of the closing balance): tax expense 1,921,076 -> 3,301,496, profit 5,779,384 -> 4,398,964, retained earnings 17,744,545 -> 16,364,125, total equity 23,726,312 -> 22,345,892, deferred tax liabilities 2,456,188 -> 3,836,608, total non-current liabilities 10316175 -> 11,696,595, EPS 252 -> 192 kobo. The primary statements print 3,301,497 (tax), 3,836,609 (deferred tax) and 11,696,596 (non-current liabilities): 1 apart from the note. Kept as printed on the statements; the starred rows are marked restated.
- Earnings per share is printed in kobo (412; 2024 restated: 192, basic and diluted, p27); stored in naira with the printed figure and unit kept.
- No emphasis-of-matter or going-concern paragraph in the auditor's report (pp22-24, page images). The auditor separately reports a limited-assurance engagement on internal control over financial reporting with no exception (assurance report also dated 31 March 2026, PDF pp25-26).
Technical details
- File
- 87 pages, with a text layer
- SHA-256
2ac3c80aa1b123eda12ef3ddf933f4decad68ebc6e337bfc3f06b49189ef86cf- Entity as printed
- Fidson Healthcare Plc
- Exchange copy
- retrieved 2026-10-08T18:00:30Z
Data notes
No figure-level notes beyond those in the tables.
Sources checked with AI assistance; independent review has not been completed. Every figure has been located on its cited source page in an AI-assisted source verification (matched to the document's text) (9 October 2026). Automated checks and the AI-assisted verification are not independent review. Methodology
Download
Figures shown on this page (CSV) — the same selected figures at their exact printed values, each with its source document, SHA-256, page, selection rule and reading. Independent review of these figures is pending.
Updates and corrections
Dated records only, newest first. Each date says what it means: when the company or exchange published a document, when our monitor first found it, when its figures were added to our data, or when a correction was applied. A correction is marked as an error in the company's report or as our own correction.
-
Summary refreshed
The business overview and financial-trend summary on this page were written from the published figures and checked against them on this date (AI-assisted verification).
-
Added to our financial data
Figures from the annual report for FY2025 added to our financial data (146 figures).